Janux Therapeutics/$JANX
Janux shares rise after Q3 losses and revenue beat expectations, while investors anticipate initial JANX011 clinical data due on Monday.
16 hours agoLightyear AI
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Janux Therapeutics
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
- Ticker
- $JANX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 113
- Headquarters
- San Diego, United States
- Website
- www.januxrx.com
JANX Metrics
BasicAdvanced
$1.1B
-
-$1.59
-
-
Price and volume
Market cap
$1.1B
52-week high
$35.34
52-week low
$12.12
Average daily volume
760K
Financial strength
Current ratio
17.685
Quick ratio
17.441
Long term debt to equity
0.019
Total debt to equity
0.022
Profitability
EBITDA (TTM)
-137.704
Gross margin (TTM)
-440.58%
Net profit margin (TTM)
-428.74%
Operating margin (TTM)
-599.26%
Revenue per employee (TTM)
$210,000
Management effectiveness
Return on assets (TTM)
-8.69%
Return on equity (TTM)
-10.58%
Valuation
Price to revenue (TTM)
47.473
Price to book
1.18
Price to tangible book (TTM)
1.18
Price to free cash flow (TTM)
-20.414
Free cash flow yield (TTM)
-4.90%
Free cash flow per share (TTM)
-0.864
Growth
Revenue change (TTM)
132.89%
Earnings per share change (TTM)
-5.24%
3-year revenue growth (CAGR)
40.11%
3-year earnings per share growth (CAGR)
2.82%
What the Analysts think about JANX
Analyst ratings (Buy, Hold, Sell) for Janux Therapeutics stock.
Analyst projections of the future price of Janux Therapeutics stock.
Bulls say / Bears say
Janux had $945.7 million in cash and short-term investments at the end of September, against a third-quarter net loss of $21.6 million. That substantial cash buffer gives it room to advance several trials without an immediate need to raise capital. (Business Wire)
Bristol Myers Squibb nominated a development candidate under its collaboration with Janux, triggering a $35 million milestone payment. The partnership provides non-dilutive funding and external support for Janux’s technology. (Janux Therapeutics)
Janux has started testing JANX013 with JANX007 in patients, adding a tumour-activated CD28 approach to its prostate cancer programme. This creates another potential clinical value driver alongside the existing T-cell engager trials. (Janux Therapeutics)
Recent reporting described high PSA response rates for JANX007 but said its RECIST response rates disappointed versus earlier data. That leaves uncertainty about whether the biomarker responses will translate into consistent tumour shrinkage. (Seeking Alpha)
Janux stopped developing JANX008 after its Phase 1a review found the overall magnitude and consistency of activity insufficient to justify further work. The decision shows that its platform does not guarantee each candidate will succeed. (Janux Therapeutics)
Much of the pipeline remains at an early stage: JANX013 has only just begun its Phase 1 combination study, JANX014 is still enrolling in Phase 1, and JANX011 is being tested in healthy volunteers. Investors therefore have limited clinical evidence for these newer programmes and no near-term commercial launch to rely on. (Business Wire)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2026.
JANX Financial Performance
Revenues and expenses
JANX Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing JANX
Fund name | Fund size | $JANX weighting |
|---|---|---|
iShares Healthcare Innovation€2B78 | $1.2B | 0.08% |
iShares Healthcare Innovation£DRDR | $1.3B | 0.08% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.08% |
iShares Ageing Population$AGED | $953M | 0.07% |
iShares Ageing Population£AGES | $953M | 0.07% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.